Plasma kinetics of mitoxantrone in leukemic patients
Medical Oncology and Tumor Pharmacotherapy · 1984
DOI: 10.1007/bf02934142 ↗At a glance
Journal article in Medical Oncology and Tumor Pharmacotherapy, 1984. Written by R Hulhoven and 2 co-authors. Cited 5 times so far (Crossref); 16 references.
Abstract (original language)
The plasma kinetics of mitoxantrone (MX), a new cytostatic anthracenedione, were investigated with HPLC in five leukemic patients suffering from acute myeloid leukemia, at the dose of 24 mg m-2 infused over 30 min at constant rate. The decay of the plasma concentrations was best fitted to a three compartment model with average elimination half-lives of respectively 4.1 min (alpha-phase), 19.8 min (beta-phase) and 8.9 h (gamma-phase), a mean distribution volume of 317 l m-2 and an average total body clearance of 0.37 l min-1 m-2. The cumulative urinary recovery of unchanged MX was 7.5% of the administered dose in 4 days, with the highest elimination during the first day. No MX urinary metabolites or conjugates have been detected.
Subjects
MeSH terms (MEDLINE)
Substances
Cite
APA
Hulhoven, R., Dumont, E., & Harvengt, C. (1984). Plasma kinetics of mitoxantrone in leukemic patients. Medical Oncology and Tumor Pharmacotherapy. https://doi.org/10.1007/bf02934142
Vancouver
Hulhoven R, Dumont E, Harvengt C. Plasma kinetics of mitoxantrone in leukemic patients. Medical Oncology and Tumor Pharmacotherapy. 1984. doi:10.1007/bf02934142
BibTeX
@article{Hulhoven1984,
author = {Hulhoven, R and Dumont, E and Harvengt, C},
title = {Plasma kinetics of mitoxantrone in leukemic patients},
journal = {Medical Oncology and Tumor Pharmacotherapy},
year = {1984},
doi = {10.1007/bf02934142}
}
EUVIMED